博爱新开源医疗科技集团股份有限公司2025年半年度报告摘要

Group 1 - The company did not distribute cash dividends or issue bonus shares during the reporting period [3] - The company’s controlling shareholder and actual controller did not change during the reporting period [5] - The company’s subsidiary, Beijing Liangyuan Biomedical Research Co., Ltd., received approval for clinical trials of a new drug for late-stage solid tumors [5][6] Group 2 - The company plans to distribute cash dividends of 2.493056 yuan per 10 shares, totaling approximately 121.18 million yuan, with the record date set for July 9, 2025 [5] - All directors attended the board meeting to review the report [2] - The company has ensured that the information disclosed is true, accurate, and complete [6]